NEWS - FDA Homeopathic Product Regulation

NEWS - FDA Hearings  

Evaluating FDA’s Regulatory Framework After a Quarter-Century

(day 1) April 20 
'The FDA hearing was wonderful. The homeopathic pharmacies and organizations presented impressive comments. The naysayers were a dim light and I thought the FDA panel was not impressed. The question is about labeling and how to make sure the public is informed to know when they are purchasing homeopathic remedies. Something that the FDA and the homeopathic community both want. I am hoping a closer collaboration is at hand. Very proud of the professional
ism and passion of the American homeopathic community.
The FDA is not concerned with efficacy but with safety, though they were curious to hear comments about "method of action." (Placebo? Nano particles? Memory of water? I vote of epigenetics.)'
Melanie Kornfeld Grimes
ALL PRESENTATIONS Outlines (pdf) at the FDA Hearings:
Here some of the Testimonies in the FDA Hearings:
Testimony by the Homeopathic Academy of Naturopathic Physicians
By Lisa Amerine, ND, DHANP
April 20, 2015

Testimony by the American Association of Naturopathic Physicians
By Amy Rothenberg, ND, DHANP
April 20, 2015

Yale Martin, Independent Retail Consultant

Presiding Officer John J. Whyte, M.D., M.P.H. Director, Professional Affairs and Stakeholder Engagement Center for Drug Evaluation and Research

Panel Members